Coeliac disease autoantibodies mediate significant inhibition of tissue transglutaminase.

The detection of antibodies directed against tissue transglutaminase (tTG) in serum is a sensitive and specific test for suspected coeliac disease. tTG is a ubiquitous, multifunctional enzyme that has been implicated in many important physiological processes as well as the site-specific deamidation of glutamine residues in gluten-derived peptides. This modification of gluten peptides facilitates their binding to HLA-DQ2, which results in amplification of the T-cell response to gluten. The purpose of this study was to investigate the possibility that patient IgA autoantibodies directed against tTG interfere with the crosslinking activity of the enzyme. IgA autoantibodies against tTG were isolated/depleted from patient serum and tested for their capacity to interfere with tTG activity in vitro using a sensitive fluorescence-based activity assay. We have demonstrated that autoantibodies cause significant inhibition of tTG-mediated crosslinking at equimolar and 2:1 ratios of antibody to enzyme.

[1]  Arthur J. L. Cooper,et al.  Mechanism for the inhibition of transglutaminase 2 by cystamine. , 2005, Biochemical pharmacology.

[2]  Mauro Piacentini,et al.  Transglutaminase 2: an enigmatic enzyme with diverse functions. , 2002, Trends in biochemical sciences.

[3]  D. Schuppan,et al.  Autoantibodies of patients with coeliac disease are insufficient to block tissue transglutaminase activity , 2003, Gut.

[4]  Ivana Caputo,et al.  Tissue transglutaminase in celiac disease: role of autoantibodies , 2009, Amino Acids.

[5]  Jangmi Hong,et al.  Structural characterization of immunoglobulin G using time-dependent disulfide bond reduction. , 2009, Analytical biochemistry.

[6]  Masashi Kikuchi,et al.  A novel function of tissue-type transglutaminase: protein disulphide isomerase. , 2003, The Biochemical journal.

[7]  Soo-Youl Kim,et al.  Increase in transglutaminase 2 expression is associated with NF-kappaB activation in breast cancer tissues. , 2009, Frontiers in bioscience.

[8]  P. Roepstorff,et al.  Molecular Characterization of Covalent Complexes between Tissue Transglutaminase and Gliadin Peptides* , 2004, Journal of Biological Chemistry.

[9]  N. Lewis,et al.  Meta‐analysis: deamidated gliadin peptide antibody and tissue transglutaminase antibody compared as screening tests for coeliac disease , 2010, Alimentary pharmacology & therapeutics.

[10]  P. Limburg,et al.  Interference of PR3‐ANCA with the enzymatic activity of PR3: differences in patients during active disease or remission of Wegener's granulomatosis , 2002 .

[11]  F. Paparo,et al.  Anti-tissue transglutaminase antibodies from coeliac patients inhibit transglutaminase activity both in vitro and in situ , 2002, Gut.

[12]  G. Melino,et al.  Tissue transglutaminase (TG2) acting as G protein protects hepatocytes against Fas‐mediated cell death in mice , 2005, Hepatology.

[13]  K. Kaukinen,et al.  Coeliac disease‐specific autoantibodies targeted against transglutaminase 2 disturb angiogenesis , 2008, Clinical and experimental immunology.

[14]  S. Kárpáti.  Dermatitis herpetiformis: close to unravelling a disease. , 2004, Journal of dermatological science.

[15]  R. Graham,et al.  The core domain of the tissue transglutaminase Gh hydrolyzes GTP and ATP. , 1997, Biochemistry.

[16]  J. Drijfhout,et al.  Specificity of Tissue Transglutaminase Explains Cereal Toxicity in Celiac Disease , 2002, The Journal of experimental medicine.

[17]  Suresh Mishra,et al.  Tissue Transglutaminase Has Intrinsic Kinase Activity , 2004, Journal of Biological Chemistry.

[18]  M. Omary,et al.  Extracellular Transglutaminase 2 Is Catalytically Inactive, but Is Transiently Activated upon Tissue Injury , 2008, PloS one.

[19]  F. Karlsson,et al.  Parietal cell antibodies in pernicious anemia inhibit H+, K+-adenosine triphosphatase, the proton pump of the stomach. , 1989, Gastroenterology.

[20]  L. Lorand,et al.  Endomysial antibody-negative coeliac disease: clinical characteristics and intestinal autoantibody deposits , 2006, Gut.

[21]  I. Korponay-Szabó,et al.  Coeliac autoantibodies can enhance transamidating and inhibit GTPase activity of tissue transglutaminase: dependence on reaction environment and enzyme fitness. , 2006, Journal of Autoimmunity.

[22]  M. Mäki,et al.  Serum immunoglobulin A from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation. , 1999, Gastroenterology.

[23]  E. Valletta,et al.  In Celiac Disease, a Subset of Autoantibodies against Transglutaminase Binds Toll-Like Receptor 4 and Induces Activation of Monocytes , 2006, PLoS medicine.

[24]  R. Giordano,et al.  Mapping of human autoantibody epitopes on aromatic L-amino acid decarboxylase. , 2007, The Journal of clinical endocrinology and metabolism.

[25]  C. Feighery,et al.  Mutagenesis of the catalytic triad of tissue transglutaminase abrogates coeliac disease serum IgA autoantibody binding , 2006, Gut.

[26]  P. Matarrese,et al.  Transglutaminase overexpression sensitizes neuronal cell lines to apoptosis by increasing mitochondrial membrane potential and cellular oxidative stress , 2002, Journal of neurochemistry.

[27]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[28]  T. Johnson,et al.  Tissue transglutaminase in normal and abnormal wound healing: Review article , 2004, Amino Acids.

[29]  G. Corazza,et al.  Coeliac disease , 2005, Journal of Clinical Pathology.